Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperbaric Oxygen Therapy in Stem Cell Transplantation
NCT03964506Phase 1Recruiting
- Start
- Jul 2020
- Primary completion
- Mar 2027
- Modality
- NPI (Non-Pharmacological Intervention)
- Countries
- 1
01
Overview
Phase 1, open-label trial of hyperbaric oxygen therapy in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and 5 more (2 cohorts). Primary endpoints: Immediate safety of hyperbaric oxygen therapy at 24 hours and Long term safety of hyperbaric oxygen therapy at 100 days. Started Jul 2020; status: recruiting.
02
Drugs
hyperbaric oxygen therapy
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)Atypical chronic myeloid leukemia (aCML)Chronic Myelomonocytic Leukemia (CMML)
Beyond the preview
Go deeper on NCT03964506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03964506.